Get the Stockscreener App
1.01
3.69%
0.0359
Vivos Therapeutics Inc stock is traded at $1.01, with a volume of 181.52K.
It is up +3.69% in the last 24 hours and down -17.21% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$0.9741
Open:
$1.01
24h Volume:
181.52K
Relative Volume:
0.97
Market Cap:
$13.62M
Revenue:
$17.44M
Net Income/Loss:
$-21.23M
P/E Ratio:
-0.4517
EPS:
-2.2361
Net Cash Flow:
$-17.60M
1W Performance:
-17.21%
1M Performance:
-17.21%
6M Performance:
-64.56%
1Y Performance:
-51.90%
1-Day Range:
$0.99
$1.0398
1-Week Range:
$0.9601
$1.54
52-Week Range:
$0.9601
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
1.01 | 13.14M | 17.44M | -21.23M | -17.60M | -2.2361 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Canada
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ACCESS Newswire
H.C. Wainwright Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $2.5 - 富途牛牛
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call Transcript - Insider Monkey
Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN
Vivos Therapeutics Balances Growth Hopes With Cash Strain - TipRanks
Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
Vivos Therapeutics Reports 16% Revenue Growth in 2025, Advances Sleep Center Integration and Eyes Cash Flow Positive Operations - Minichart
Vivos Therapeutics Pivots to Medical-Provider Focused Model with Sleep Center of Nevada Acquisition to Expand Sleep Apnea Solutions 91 - Minichart
Earnings call transcript: vivos beats Q4 2025 earnings expectations - Investing.com UK
VVOS: 2025 revenue rose 16% as SCN integration fueled growth, with further expansion planned for 2026 - TradingView
Earnings Call Summary | Vivos Therapeutics(VVOS.US) Q4 2025 Earnings Conference - 富途牛牛
VVOS: 2025 revenue up 16% from SCN integration, with strong growth outlook as new model scales - TradingView
Earnings call transcript: vivos beats Q4 2025 earnings expectations By Investing.com - Investing.com India
Vivos Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Form 8-KCurrent report - ADVFN
Vivos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vivos Therapeutics (NASDAQ: VVOS) details SCN deal and new sleep-center strategy - Stock Titan
Vivos Therapeutics Reports Full Year 2025 Financial Results - The Manila Times
Vivos grows on sleep apnea services, but operating loss hits $19.9M - Stock Titan
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results - National Today
Vivos Therapeutics, Inc. to Release Full Year 2025 Financial Results and Conduct Conference Call on April 15, 2026 - Quiver Quantitative
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call - marketscreener.com
Vivos investors get 2025 results and strategy update at 5 p.m. ET - Stock Titan
Vivos Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ - ACCESS Newswire
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX) - Hilton Head Island Packet
Vivos Therapeutics (VVOS) 10% holder reports large stock and warrant stakes - Stock Titan
VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
Resistance Check: Can Vivos Therapeutics Inc maintain its current growth rate2026 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
VVOS|Vivos Therapeutics Inc|Price:1.190|Chg%:-0.05 - TradingKey
VVOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vivos Therapeutics closes $2.25M private placement with Seneca By Investing.com - Investing.com Canada
Vivos Therapeutics closes $2.25M private placement with Seneca - Investing.com
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners - marketscreener.com
Sleep-disorder company Vivos gets $2.25M from repeat investor - Stock Titan
Portfolio Update: How does Vivos Therapeutics Inc score in quality rankingsTrade Exit Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into MondayBroadcom (NASDAQ:AVGO) - Benzinga
Vivos Therapeutics Enters Securities Purchase Agreement with V-CO Investors 3 LLC and Issues New Warrants – Form 8-K Filing Details - Minichart
VVOS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VVOS Technical Analysis & Stock Price Forecast - Intellectia AI
If You Invested $1,000 in Vivos Therapeutics Inc (VVOS) - Stock Titan
Vivos Therapeutics Completes Private Placement to Bolster Liquidity - The Globe and Mail
Vivos Therapeutics Secures $0.85M PIPE, Converts $1.4M Bridge Note With Seneca Affiliate - TradingView — Track All Markets
Vivos Therapeutics (NASDAQ: VVOS) gets $850,000 PIPE cash plus $1,400,000 bridge note conversion - Stock Titan
Why did Vivos Therapeutics (VVOS) stock jump over 21% after hours - MSN
Vivos Therapeutics investor V-Co investors 3 LLC buys shares worth $1.8m By Investing.com - Investing.com
Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours - Benzinga
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):